Indoles for use in influenza virus infection

Patent metadata

Field	Value
Publication number	US-2017226102-A1
Application number	US-201515501730-A
Country	US
Kind code	A1
Filing date	Aug 7, 2015
Priority date	Aug 8, 2014
Publication date	Aug 10, 2017
Grant date	—

Abstract

The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.

First claim

1 . A compound of formula (I)

a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein
X is N or C wherein when X is C, then X is optionally substituted by —CN, —CF 3 , —C 1-3 alkyl-NH—C(O)—C 1 -3 alkyl, —C(O)—NH 2 , —C(O)—NH—C 1-3 alkyl, —C(O)—N-(dialkyl) or —CH 2 —NH—C(O)—CH 3 ;
R 1 is F or Cl;
each of R 2 and R 4 is independently H, halogen, CN, CF 3 , —O-alkyl or NH 2 ;
R 3 is F, Cl, CN, CF 3 , —C 1-3 alkyl, —O-alkyl, carboxylic ester or carboxylic amide;
R 5 is Br, CN, CH 3 , CH 2 OH, C(O)NH 2 , NH 2 or H;
R 6 is C 1-8 alkyl substituted by carboxylic acid; C 3-8 cycloalkyl substituted by carboxylic acid, —N—C 1-3 alkylsulfone, —N—C(O)—C 3-6 heterocycle optionally substituted by C 1-6 alkyl; C 3-6 heterocycle substituted by —N—C(O)—C 3-6 heterocycle; or C 3-6 heterocycle substituted by COOH.

2 . A compound according to claim 1 wherein R 1 is F and R 3 is F.

3 . A compound according to claim 1 having the structural formula

4 . A pharmaceutical composition comprising a compound of formula (I) or a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.

5 . (canceled)

6 . A method of treating influenza, comprising administering a therapeutically effective amount of at least one compound as claimed in claim 1 .

7 . A method of inhibiting the replication of the influenza virus in a biological sample or patient, comprising administering a therapeutically effective amount of at least one compound as claimed in claim 1 .

8 . The method as claimed in claim 7 further comprising co-administering an additional therapeutic agent.

9 . The method as claimed in claim 8 wherein the additional therapeutic agent is selected from an antiviral agent or influenza vaccine, or both.

Assignees

• Janssen Sciences Ireland Uc

Inventors

• Jonckers Tim Hugo Maria
• Raboisson Pierre Jean-Marie Bernard
• Guillemont Jérôme Émile Georges
• Mc Gowan David Craig
• Embrechts Werner Constant Johan
• Cooymans Ludwig Paul
• Michaut Antoine Benjamin

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title